CJC-1295 (No DAC) | 10mg Lyophilized

Description

CJC-1295 (No DAC) 10mg Vial – Pharmaceutical-Grade GHRH Analogue for Natural Growth Hormone Release 

CJC-1295 (No DAC) is a synthetic analogue of growth hormone-releasing hormone (GHRH), designed to stimulate endogenous growth hormone (GH) secretion through activation of GHRH receptors on somatotroph cells in the anterior pituitary gland. It is a shortened-acting variant of CJC-1295 that has been structurally optimized to preserve receptor activity while avoiding prolonged systemic binding characteristics.

Unlike the DAC (Drug Affinity Complex) version, CJC-1295 No DAC does not incorporate albumin-binding modifications. As a result, it exhibits a significantly shorter plasma half-life and promotes a more physiological, pulsatile pattern of GH release. This pharmacokinetic profile is considered particularly relevant in research settings where endogenous-like hormone dynamics are being evaluated.

CJC-1295 No DAC is commonly studied as a tool compound for examining growth hormone axis regulation, hypothalamic–pituitary feedback loops, and downstream insulin-like growth factor-1 (IGF-1) signaling. Its pulsatile activity profile makes it useful for comparative studies against long-acting GHRH analogues and secretagogues.

Product Contents

• 10mg CJC-1295 (No DAC) Lyophilised powder
• Bacteriostatic Water
• 10 Sterile syringes

What Is It Used For and Its Purpose 

CJC-1295 No DAC is primarily used in research to evaluate short-acting stimulation of the GHRH receptor and its effects on endogenous growth hormone secretion patterns. Due to its brief half-life, it is particularly useful in studies investigating pulsatile endocrine signaling rather than sustained hormonal elevation.

It is widely applied in comparative pharmacology to assess how transient versus prolonged GH stimulation influences metabolic pathways, feedback regulation of the hypothalamic–pituitary axis, and downstream IGF-1 signaling. This makes it a valuable tool in distinguishing receptor-level kinetics from systemic hormonal outcomes. Research applications include:

• Endocrinology (growth hormone axis dynamics)
• Metabolism (glucose and lipid regulation models)
• Receptor signaling (GHRH receptor activation kinetics)
• Aging research (pulsatile GH secretion studies)
• Neuroendocrinology (hypothalamic–pituitary feedback research)

Potential Scientific Benefits 

Preclinical research on GHRH analogues suggests that compounds such as CJC-1295 No DAC may influence endocrine and metabolic pathways through transient stimulation of growth hormone release. Its short-acting profile provides a model for studying physiological GH pulsatility, which is an important feature of normal endocrine function.

In experimental systems, pulsatile GH signaling has been associated with modulation of anabolic pathways, substrate metabolism, and hormone feedback regulation. However, findings are dependent on model systems and dosing patterns, and should not be interpreted as established clinical outcomes. Observed and reported research activities include:

• Transient increases in growth hormone secretion in experimental models
• Modulation of IGF-1 signaling downstream of GH pulses
• Influence on lipolysis and energy substrate utilization pathways
• Regulation of protein synthesis signaling cascades in preclinical systems
• Contribution to studies on endocrine rhythm and feedback control mechanisms

Current evidence remains limited, and further well-controlled clinical studies are required to establish long-term efficacy and safety in humans.

Research Data Sheet 

This section summarizes key physicochemical and identification data relevant for laboratory research use.

• Peptide: CJC-1295 (No DAC)
• Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg
• Classification: Synthetic GHRH analogue
• Molecular Formula: C165H269N47O46
• Molecular Weight: ~3647.2 g/mol
• CAS Number: 863288-34-0
• Form: Lyophilized powder
• Appearance: White to off-white solid
• Purity: ≥98%
• Solubility: Sterile water or bacteriostatic water under laboratory conditions
• Storage: 2–8°C short term; -20°C long term; protect from light
• Research Categories: Endocrinology, GH/IGF-1 axis research, metabolic regulation, neuroendocrinology, receptor pharmacology

Safety Precautions 

CJC-1295 (No DAC) is intended strictly for laboratory research use only and is not approved for human consumption, diagnostic procedures, or therapeutic application. It should only be handled by qualified personnel under appropriate laboratory conditions.

• Research use only
• Not for human consumption
• Not intended to diagnose, treat, cure, or prevent any disease
• Use appropriate PPE (gloves, lab coat, eye protection)
• Maintain aseptic handling techniques
• Store under recommended refrigeration/freezing conditions
• Avoid repeated freeze–thaw cycles
• Ensure correct labeling and secure containment
• Dispose of waste according to institutional and regulatory guidelines
• Limited long-term human safety data available
• Potential endocrine activity requires controlled experimental design

Conclusion 

CJC-1295 No DAC is a short-acting synthetic GHRH analogue used extensively in research focused on growth hormone pulsatility and endocrine regulation. Its lack of albumin-binding modification results in a brief activity window, making it particularly suitable for studying physiological GH secretion patterns rather than sustained hormonal elevation.

This compound is valuable in experimental models investigating metabolic regulation, IGF-1 signaling, and hypothalamic–pituitary feedback control. Its pharmacokinetic profile allows researchers to isolate the effects of transient GH stimulation in comparison with longer-acting analogues.